In a strategic move to reinforce its oncology pipeline, Merck & Co. has agreed to acquire Terns Pharmaceuticals in a deal valued at approximately US$6.7 B. Through the transaction, Merck picks up full rights to TERN-701, an investigational oral therapy for chronic myeloid leukaemia (CML), enhancing its portfolio of next-generation cancer treatments. The acquisition comes as Merck prepares for the 2028 patent expiration of Keytruda, a therapy that currently contributes nearly half of its revenue. By securing TERN-701, Merck aims to sustain its long-term growth and reduce its reliance on Keytruda revenue.